SOURCE: TomoTherapy


December 01, 2010 13:30 ET

TomoTherapy Sponsors American Cancer Society's Fall 2010 Matching Grant Challenge

TomoTherapy to Match up to $100,000 in Donations by Dec. 15

MADISON, WI--(Marketwire - December 1, 2010) -  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that it is the exclusive sponsor of the American Cancer Society's Fall 2010 Matching Grant Challenge, a national fundraising campaign that was launched in November.

As sponsor, TomoTherapy will contribute $1 for every $1 donated by the general public, up to $100,000, to support the American Cancer Society's efforts to help people stay well and get well from cancer, find cures, and fight back against the disease. The Matching Grant Challenge ends on December 15, 2010.

"Every day, TomoTherapy's innovative radiation therapy solution helps patients fight cancer. With our support of the American Cancer Society, we extend our impact beyond technology," said Fred Robertson, M.D., TomoTherapy's CEO. "In matching the generous contributions of individuals, TomoTherapy proudly strengthens the efforts of the American Cancer Society -- from funding groundbreaking research to providing resources for patients, their families and caregivers at every step in the cancer experience."

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Contact Information

  • Media Contacts:
    Kevin O'Malley
    Manager, Corporate Communications
    Email Contact

    Susan Lehman
    Rockpoint Public Relations
    Email Contact